OKYO Pharma
OKYO
1 hedge funds and large institutions have $3K invested in OKYO Pharma in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
67% less funds holding
Funds holding: 3 → 1 (-2)
95% less capital invested
Capital invested by funds: $62K → $3K (-$59K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$54K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $3K | -$5.98K | -2,485 | -68% |
|
|
2
Citadel Advisors
Miami,
Florida
| – | -$54K | -26,864 | Closed |
|
OKYO Hedge Fund Activity: Q3 2022 in Review
1 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q3 2022, worth a combined $3K — down 95% from $62K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of OKYO and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $54K sold.
- 1 institutional investor held OKYO Pharma (OKYO) as of Q3 2022, down from 3 in Q2 2022.
- Funds reported $3K of OKYO Pharma stock for Q3 2022, down 95% quarter-over-quarter.
- 0 funds opened new OKYO Pharma positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest OKYO Pharma seller in Q3 2022 was Citadel Advisors, an estimated $54K sold.
Based on aggregated 13F filings for Q3 2022.